Eurofins Viracor expands and moves to a new, 110,000 ft² purpose-built facility in Lenexa, KS

Doug Irving, Director of Marketing, Eurofins Viracor BioPharma Services, DougIrving@eurofins-viracor.com

Eurofins Viracor is excited to share that it recently completed the construction of a new state-of-the-art facility and has officially relocated to a beautiful new home in Lenexa, Kansas. The new structure will house Eurofins Viracor company headquarters, along with all laboratory testing equipment and personnel.

The relocation and expansion, in response to continual growth in client demand, are consistent with its organisational goal of providing more comprehensive solutions for clients. Building on a new site afforded the company the opportunity to create a purpose-built facility where it can maximise flexibility and efficiency of operations. Moreover, as current and future testing demand has continued to grow, Eurofins Viracor was on track to exceed the capacity of the current location within the next few years. The new, 110,000 ft² facility nearly doubles the previous footprint, enabling Viracor to address increasing demand for molecular and immuno-assay development and testing services to support growth in vaccine and precision oncology development.

The move itself was a resounding success, without disrupting any services during the relocation. Similarly, Viracor has also avoided any significant delays to ongoing client projects or studies as a result of the move. This success is attributed to a combination of the tenacious project leadership of the former President, Scott Mattivi, the many duplicate systems that were temporarily established at both sites to help ensure a smooth transition, and the heroic efforts of a great many dedicated associates and partners.

The company will occupy all of the new facility, which allows for expanded molecular/genomic, next generation sequencing, immunoassay, cell-based, LCMS, and other bioanalytical testing services. This is in addition to increased processing automation and ultralow biostorage capabilities to ensure Viracor is positioned to meet the changing needs of clients well into the future.

Triggered by continued growth and client-focused strategic expansion, Eurofins Viracor has created a space that encourages collaboration to help facilitate the development of life-advancing therapies across the globe. The team looks forward to continuing to provide quality results and excellent service from the new facility.

The address of the new facility is:

Eurofins Viracor BioPharma Services
18000 West 99th Street
Lenexa, KS 66219

For more information, visit: www.eurofins-viracor.com/biopharma/